New York is currently home to 4599 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Ortho-R® for Rotator Cuff Repair Compared With Standard of Care Rotator Cuff Repair Without Ortho-R®
Recruiting
Phase I/II, multi-center, prospective, blinded 2arm, parallel design and randomized controlled study. Assessing the Ortho-R/PRP combination and standard of care for rotator cuff repair, will be compared though 12 months.
Gender:
All
Ages:
Between 40 years and 75 years
Trial Updated:
03/17/2023
Locations: University of Buffalo Orthopaedic & Sports Medicine, Buffalo, New York
Conditions: Rotator Cuff Tears
Physica System Total Knee Replacement Registry Study
Recruiting
The primary objective of this study is to obtain long-term implant survivorship (out to 10 years) and to assess clinical, patient-reported outcome measures, and radiographic data for the commercially available Physica system. For ancillary arm, from baseline to 5-year follow-up.
Gender:
All
Ages:
22 years and above
Trial Updated:
03/17/2023
Locations: Syracuse Orthopedic Specialists, Syracuse, New York
Conditions: Osteoarthritis, Knee, Traumatic Arthritis, Avascular Necrosis, Degenerative Joint Disease of Knee, Rheumatoid Arthritis, Deformity of Knee
Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Study in Ulcerative Colitis
Recruiting
Prospective, single-center, sham-controlled, double-blinded 12-week study designed to evaluate the safety and efficacy of the RAVANS device in subjects with Ulcerative Colitis. The goal of the study is to distinguish sham (no stimulation) versus treatment (stimulation) response and to identify treatment responders. The study will last 12 weeks with in-clinic visits at 0 weeks and 12 weeks, and a telehealth-visit at week 6. Additionally, unscheduled visits may occur based on the needs of the subj... Read More
Gender:
All
Ages:
Between 10 years and 39 years
Trial Updated:
03/16/2023
Locations: Feinstein Institute for Medical Research at Northwell Health, Lake Success, New York
Conditions: Ulcerative Colitis
Modular Approach for Autism Programs in Schools
Recruiting
The number of students aged 6-21 years with an educational classification of autism spectrum disorder (ASD) in the United States grew by about 19 times over a 19-year period-from 29,076 in 1995-6 to 545,198 in 2014-2015 (IDEA Data Center, 2018). Meeting the needs of this growing population of students is a significant concern for schools (Bowen, 2014). Investigators have described as many as 27 efficacious intervention strategies for teaching new skills to children with ASD (Wong et al., 2015).... Read More
Gender:
All
Ages:
Between 5 years and 12 years
Trial Updated:
03/15/2023
Locations: University of Rochester, Rochester, New York
Conditions: Autism Spectrum Disorder
A Study of ICP-192 in Patients With Advanced Solid Tumors
Recruiting
This is a multi-center, open-label, phase I/II clinical study to evaluate ICP-192 in patients with advanced solid tumors and FGFR gene alterations. It consists of two parts: Part I (Phase I), dose escalation and Part II (Phase II), dose expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2023
Locations: Rutgers Cancer Institute of New Jersey, Bronx, New York
Conditions: Advanced Solid Tumors, Urothelial Carcinoma, Cholangiocarcinoma
Hydroxyurea Optimization Through Precision Study
Recruiting
Hydroxyurea Optimization through Precision Study (HOPS) is a prospective, multi-center, randomized trial that will directly compare a novel, individualized dosing strategy of hydroxyurea to standard weight-based dosing for children with SCA. The primary objective of the study is to evaluate whether a pharmacokinetics-based starting hydroxyurea dose thieves superior fetal hemoglobin response to to standard weight-based initial dosing. Patients will be recruited from the pediatric sickle cell clin... Read More
Gender:
All
Ages:
Between 6 months and 21 years
Trial Updated:
03/09/2023
Locations: Cohen Children's Medical Center/Northwell Health, New Hyde Park, New York
Conditions: Sickle Cell Disease, Sickle Cell Anemia
SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
Recruiting
This is a Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of AR-501 (gallium citrate) solution, administered via inhalation, in healthy adult and P. aeruginosa infected cystic fibrosis (CF) subjects. Phase 1 of the study in HV subjects will consist of a single-ascending-dose (SAD) cohort, followed by the HV multiple-ascending-dose (MAD) cohort. Phase 2a of the study in CF subjects will consist of a MAD study design. The study will evaluate the safety and pharmaco... Read More
Gender:
All
Ages:
Between 18 years and 49 years
Trial Updated:
03/07/2023
Locations: Research Site, New York, New York
Conditions: Cystic Fibrosis
Evaluation of Efficacy and Safety of the triLift™ System
Recruiting
Single center, single-arm, prospective, open Label with Before & After Study Design.
Gender:
All
Ages:
Between 35 years and 55 years
Trial Updated:
03/06/2023
Locations: NY Laser Skin Care, New York, New York
Conditions: Skin Laxity, Wrinkle
Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)
Recruiting
This study aims to compare treatment with Imipenem/Cilastatin-XNW4107 (IMI-XNW4107) with imipenem/cilastatin/relebactam (IMI/REL) in participants with hospital-acquired or ventilator-associated bacterial pneumonia (HABP or VAPB, respectively). The primary hypothesis is that IMI-XNW4107 is non-inferior to IMI/REL in all-cause mortality.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/06/2023
Locations: VA medical center, Buffalo, New York
Conditions: Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
Feasibility of Non-Operative Management of Rectal Cancer in a Rural Population
Recruiting
This is an observational research study. Patients with rectal cancer can choose different courses of treatment. This study will follow these patients over the course of approximately six years, depending on their treatment. Patients will be monitored through clinic visits and survey assessments to see how they do, how they feel regarding their treatment choices, and their outcomes. The surveys will analyze the impact of the patients' treatment choices, as well as patient adherence, in a rural se... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: Bassett Healthcare Network, Cooperstown, New York
Conditions: Rectal Cancer
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
Recruiting
This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELx HER2 Signaling Function (HSF) testing.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: University of Rochester - Wilmot Cancer Institute, Rochester, New York
Conditions: HER2-negative Breast Cancer
A Therapeutic Experience Program (TEP) Study for Improvement of Gait in People With Multiple Sclerosis (MS)
Recruiting
PoNS therapy is a rehabilitation program that uses the PoNS device in conjunction with individualized physical exercise. This is an outcome research open label observational interventional multi-center study investigating the relationship between subject's adherence to PoNS therapy and therapeutic outcomes.
Gender:
All
Ages:
Between 22 years and 65 years
Trial Updated:
03/02/2023
Locations: NYU Langone Health, NYU Grossman School of Medicine, New York, New York
Conditions: Gait Impairment Due to Mild/Moderate Multiple Sclerosis (MS)